The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

Radin, Massimo; Sciascia, Savino; Erkan, Doruk; Pengo, Vittorio; Tektonidou, Maria G.; Ugarte, Amaia; Meroni, Pier Luigi; Ji, Lanlan; Belmont, H. Michael; Cohen, Hannah; Jesús, Guilherme Ramires de; Branch, D. Ware; Fortin, Paul R.; Andréoli, Laura; Petri, Michelle; Rodríguez, Esther; Rodríguez‐Pintó, Ignasi; Knight, Jason S.; Atsumi, Tatsuya; Willis, Rohan; González, Emilio B.; López-Pedrera, Rosario; Gândara, Ana Paula Rossi; Vendramini, Margarete Borges Galhardo; Banzato, Alessandra; Sevim, Ecem; Barbhaiya, Medha; Efthymiou, Maria; Mackie, Ian; Bertolaccini, Maria Laura; Andrade, Danieli

doi:10.1016/j.semarthrit.2019.04.009

Cited by 94 publications

(71 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on additional registry analyses completed over the last decade, APS ACTION investigators demonstrated that (a) the adjusted global APS Score (aGAPSS) might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS [ 13 ]; (b) younger age at diagnosis of obstetric APS, additional CVD risk factors, history of superficial vein thrombosis and heart valve disease, multiple aPL test positivity, and higher aGAPSS at the registry entry increase the risk of thrombosis after initial pregnancy morbidity [ 14 ]; and (c) combined antiplatelet and anticoagulant therapy, compared to single therapy, may decrease the rate of and increase the time to thrombosis recurrence in patients with APS presenting with arterial thrombosis [ 15 ].…”

Section: –2020: the Evolution Of Aps Actionmentioning

confidence: 99%

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

et al. 2021

Self Cite

View full text Add to dashboard Cite

Purpose of Review APS ACTION is an international research network created to design and conduct large-scale, multicenter research in persistently antiphospholipid antibody (aPL)–positive patients. Given the expanding research activities of the network in the last decade since its creation, the purpose of this article is to review the scientific contributions of APS ACTION as well as future directions. Recent Findings APS ACTION has achieved increased international collaboration with internal and external investigators for outcome, interventional, and mechanistic antiphospholipid syndrome (APS) studies. This has been linked to substantial progress in Core laboratory work, which has demonstrated that laboratories can achieve good agreement in performance of aPL assays by use of the same reagents, analyzer type, and protocols. Summary APS ACTION will continue to identify gaps in the existing aPL/APS literature, design mechanistic studies to elucidate underlying mechanisms, and conduct prospective, large-scale clinical studies, all for the ultimate goal of early diagnosis and improved management of aPL-positive patients.

show abstract

Section: –2020: the Evolution Of Aps Actionmentioning

confidence: 99%

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…14 In fact, CVD risk factors are now incorporated into thrombosis prediction models. 15 , 16 Lastly, overlapping manifestations exist between SLE and APS. While aPL modify the clinical presentation of SLE patients, 17–19 conversely, SLE could also modify the clinical presentation of aPL-positive patients.…”

Section: Discussionmentioning

confidence: 99%

Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry

Zuily

Clerc‐Urmès

Bauman

et al. 2020

Lupus

Self Cite

View full text Add to dashboard Cite

Objective This study aimed to use cluster analysis (CA) to identify different clinical phenotypes among antiphospholipid antibodies (aPL)-positive patients. Methods The Alliance for Clinical Trials and International Networking (APS ACTION) Registry includes persistently positive aPL of any isotype based on the Sydney antiphospholipid syndrome (APS) classification criteria. We performed CA on the baseline characteristics collected retrospectively at the time of the registry entry of the first 500 patients included in the registry. A total of 30 clinical data points were included in the primary CA to cover the broad spectrum of aPL-positive patients. Results A total of 497 patients from international centres were analysed, resulting in three main exclusive clusters: (a) female patients with no other autoimmune diseases but with venous thromboembolism (VTE) and triple-aPL positivity; (b) female patients with systemic lupus erythematosus, VTE, aPL nephropathy, thrombocytopaenia, haemolytic anaemia and a positive lupus anticoagulant test; and (c) older men with arterial thrombosis, heart valve disease, livedo, skin ulcers, neurological manifestations and cardiovascular disease (CVD) risk factors. Conclusions Based on our hierarchical cluster analysis, we identified different clinical phenotypes of aPL-positive patients discriminated by aPL profile, lupus or CVD risk factors. Our results, while supporting the heterogeneity of aPL-positive patients, also provide a foundation to understand disease mechanisms, create new approaches for APS classification and ultimately develop new management approaches.

show abstract

“…79 The adjusted GAPSS has been applied to asses the risk of recurrent thrombosis in the APS ACTION cohort and for risk stratification in young APS patients with acute myocardial infarction. 80,81 Statins: Obstetric APS. The global prevalence of preeclampsia, a leading cause of maternal and fetal mortality, is estimated to be 4.6% (95% CI 2.7%-8.2%) of primigravidae.…”

Section: Statinsmentioning

confidence: 99%

Section: Adjunctive Therapiesmentioning

confidence: 99%

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Cohen

Cuadrado

Erkan

et al. 2020

Lupus

Self Cite

101

112

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index.

show abstract

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

Abstract: Objectives:

Cited by 94 publications

References 18 publications

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update

Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Contact Info

Product

Resources

About